Compare BOTJ & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | ALXO |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 79.7M |
| IPO Year | N/A | 2020 |
| Metric | BOTJ | ALXO |
|---|---|---|
| Price | $18.54 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 4.7K | ★ 194.6K |
| Earning Date | 01-30-2026 | 11-07-2025 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $47,669,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.64 | ★ N/A |
| Revenue Growth | ★ 8.53 | N/A |
| 52 Week Low | $11.56 | $0.40 |
| 52 Week High | $18.55 | $2.27 |
| Indicator | BOTJ | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 49.15 |
| Support Level | $17.76 | $1.29 |
| Resistance Level | $18.50 | $1.57 |
| Average True Range (ATR) | 0.36 | 0.11 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 99.37 | 55.00 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.